Vasomune Therapeutics Appoints Douglas A. Hamilton as President and Chief Executive Officer
Vasomune Therapeutics, a leading biotechnology company developing therapeutics targeting vascular dysfunction and inflammation, announced that Douglas A. Hamilton has been appointed President and Chief Executive Officer of the company.